SGEN - Seattle Genetics, Inc.
| Previous Close | 54.39 |
| Open | 54.63 |
| Bid | 18.44 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 54.05 - 58.50 |
| 52 Week Range | 47.75 - 84.37 |
| Volume | 3,318,179 |
| Avg. Volume | 1,035,312 |
| Market Cap | 9.197B |
| Beta (3Y Monthly) | 2.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.06 |
| Earnings Date | Feb 4, 2019 - Feb 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 80.36 |
- MarketWatch•3 days ago
Seattle Genetics stock jumps 6% after new FDA approval for lymphoma treatment
Shares of Seattle Genetics Inc. rose more than 6% Friday, after the company said it had received a new approval for its Adcetris therapy as a treatment for previously untreated peripheral T-Cell Lymphoma. The U.S. Food and Drug Administration approved Adcetris in combination with CHP chemotherapy based on the successful outcome of its phase 3 ECHELON-2 clinical trial, the company said in a statement. The FDA used a new approval pathway that allowed it to come just two weeks after the company submitted data and just under two months since it announced topline data. "While this approval was widely anticipated given the Overall Survival benefit and positive trial (ECHELON-2), we believe SGEN shares will react favorably given that it suggests PTCL revenues are likely to start in Q4, and also dispels any risk from the upcoming American Society of Hematology (ASH) presentation, especially in regards to the broader, non-ALCL (anaplastic large cell lymphoma ) cohort, which were included in this label," said Leerink analyst Andrew Berens. Leerink was previously expected revenue to start in 2019. It is the sixth FDA-approved indication for Adcetris. Shares have gained 7% in 2018, while the S&P 500 has gained 2%.
- Business Wire•3 days ago
Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas
-First FDA-Approved Regimen in Frontline Peripheral T-Cell Lymphoma-
- Zacks•3 days ago
Seattle Genetics' Adcetris Gets Breakthrough Therapy Status
Seattle Genetics' (SGEN) Adcetris gets Breakthrough Therapy designation by the FDA for the frontline treatment of certain lymphoma subtypes.
- Business Wire•4 days ago
FDA Grants Breakthrough Therapy Designation to ADCETRIS® (Brentuximab Vedotin) for Frontline Peripheral T-Cell Lymphomas
-Designation Based on Positive Phase 3 ECHELON-2 Trial Evaluating ADCETRIS in Frontline CD30-Expressing Peripheral T-Cell Lymphomas; Data to be Presented at Upcoming American Socie
- Business Wire•5 days ago
Seattle Genetics Initiates Phase 1 Clinical Trial of SEA-BCMA for Patients with Relapsed or Refractory Multiple Myeloma
-SEA-BCMA is a Novel Empowered Antibody Targeting BCMA for Multiple Myeloma-
Markit•10 days agoSee what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGEN
- ACCESSWIRE•11 days ago
Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Seattle Genetics
NEW YORK, NY / ACCESSWIRE / November 8, 2018 / U.S. markets advanced on Wednesday as the midterm election results went according to market expectations. The Democrats took over the House, while the Republicans ...
- Business Wire•13 days ago
Seattle Genetics to Present at the Credit Suisse 27th Annual Healthcare Conference
Seattle Genetics, Inc. announced today that management will present at the Credit Suisse 27th Annual Healthcare Conference on Tuesday, November 13, 2018 at 2:15 p.m. Mountain Time.
- Business Wire•14 days ago
Seattle Genetics Submits Supplemental Biologics License Application for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
-Submission Based on Positive Phase 3 ECHELON-2 Trial Evaluating ADCETRIS in Frontline CD30-Expressing Peripheral T-Cell Lymphoma-
- Thomson Reuters StreetEvents•16 days ago
Edited Transcript of SGEN earnings conference call or presentation 25-Oct-18 8:30pm GMT
Q3 2018 Seattle Genetics Inc Earnings Call
- American City Business Journals•16 days ago
Microsoft and Seattle Genetics buildings are part of a big Bothell sale
The 17-building property is essentially full with medical device manufacturing, aerospace and telecomm companies also operating there.
- Business Wire•18 days ago
Seattle Genetics Announces More Than 30 Presentations at ASH 2018 Highlighting Progress with Broad ADCETRIS® (Brentuximab Vedotin) Development Program
-Positive Phase 3 ECHELON-2 Clinical Trial Results to be Presented in Oral Session on Monday, December 3rd-
- GlobeNewswire•19 days ago
New Research: Key Drivers of Growth for Covanta Holding, Seattle Genetics, DSW, Canada Goose, Oaktree Capital Group, and Arthur J. Gallagher — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Oct. 31, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Motley Fool•20 days ago
Seattle Genetics: "Now the Hard Work Begins"
Front-line Hodgkin lymphoma turns out to be a tough market to crack.
- Zacks•24 days ago
Seattle Genetics (SGEN) Q3 Loss In Line, Sales Top Mark
Seattle Genetics' (SGEN) loss matches estimates but rides high on revenue beat in Q3.
- Motley Fool•24 days ago
Here's Why Seattle Genetics Plummeted Today
Third-quarter earnings weren't what investors (or management) were hoping for.
- Benzinga•24 days ago
The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Oct. 26) Endocyte, Inc. (NASDAQ: ECYT ) Imprimis Pharmaceuticals ...
Motley Fool•24 days agoSeattle Genetics Inc (SGEN) Q3 2018 Earnings Conference Call Transcript
SGEN earnings call for the period ending September 30, 2018.
- Associated Press•25 days ago
Seattle Genetics: 3Q Earnings Snapshot
The Bothell, Washington-based company said it had a loss of 42 cents per share. Losses, adjusted for investment costs, came to 27 cents per share. The results matched Wall Street expectations. The average ...
- Business Wire•25 days ago
Seattle Genetics Reports Third Quarter 2018 Financial Results
-ADCETRIS® Net Sales in U.S. and Canada of $127.0 Million in the Third Quarter-
- Zacks•27 days ago
Seattle Genetics Sees Hammer Chart Pattern: Time to Buy?
Seattle Genetics has been struggling lately, but the selling pressure may be coming to an end soon.
Markit•last monthSee what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGEN
Market Realist•last monthHow Acadia Pharmaceuticals Is Positioned Financially
Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will generate revenues of $56.07 million in the third quarter of 2018, representing a ~57.59% YoY (year-over-year) growth. Its net revenues grew ~87% to $57.06 million in the second quarter, from $30.5 million in the second quarter of 2017.
Market Realist•last monthAnalysts Mostly Positive on Acadia Pharmaceuticals
Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will report net income of -$63.01 million for the third quarter of 2018. It was -$63.3 million in the second quarter, which compares to -$67.4 million in the second quarter of 2017. In the first half of this year, its net income was -$117.66 million. In the first half of 2017, it was -$155.3 million.
